A Phase I/II, Randomized, Double-Blind Intervention Trial for Evaluating the Safety and Efficacy of Imatinib in Subjects with Advance fibrosis
Latest Information Update: 04 Jan 2024
Price :
$35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Hepatic fibrosis
- Focus Pharmacodynamics; Therapeutic Use
- 24 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2020 New trial record